The estimated Net Worth of Edward Morrow Iii Atkinson is at least $5.22 Million dollars as of 11 June 2024. Edward Atkinson owns over 7,288 units of 89bio Inc stock worth over $129,533 and over the last 2 years Edward sold ETNB stock worth over $5,086,835.
Sign up
Edward Atkinson ETNB stock SEC Form 4 insiders trading
Edward has made over 7 trades of the 89bio Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Edward sold 7,288 units of ETNB stock worth $3,483,664 on 11 June 2024.
The largest trade Edward's ever made was exercising 10,000 units of 89bio Inc stock on 1 March 2023 worth over $44,400. On average, Edward trades about 2,278 units every 39 days since 2022. As of 11 June 2024 Edward still owns at least 15,972 units of 89bio Inc stock.
You can see the complete history of Edward Atkinson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Edward Atkinson's mailing address?
Edward's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.
Insiders trading at 89bio Inc
Over the last 5 years, insiders at 89bio Inc have traded over $17,267,666 worth of 89bio Inc stock and bought 14,519,952 units worth $208,678,684 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ..., and Advisors Llc Orbi Med Capit.... On average, 89bio Inc executives and independent directors trade stock every 28 days with the average trade being worth of $2,197,340. The most recent stock trade was executed by Rohan Palekar on 1 April 2024, trading 52,718 units of ETNB stock currently worth $575,153.
What does 89bio Inc do?
89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.
What does 89bio Inc's logo look like?
Complete history of Edward Atkinson stock trades at Vertex Pharmaceuticals and 89bio Inc
89bio Inc executives and stock owners
89bio Inc executives and other stock owners filed with the SEC include:
-
Rohan Palekar,
Chief Executive Officer, Director -
Rohan Palekar,
CEO & Director -
Hank Mansbach,
Chief Medical Officer -
Dr. Harry Mansbach M.D.,
Chief Medical Officer -
Dr. Hank Mansbach M.D.,
Chief Medical Officer -
Quoc Le-Nguyen,
Chief Technical Operations Officer and Head of Quality -
Quoc Le-Nguyen,
Chief Technical Operations Officer & Head of Quality -
Ram Waisbourd,
Chief Operating Officer and Chief Business Officer -
Michael Hayden,
Independent Director -
Anat Naschitz,
Independent Director -
Gregory Grunberg,
Independent Director -
Derek DiRocco,
Independent Director -
Ryan Martins,
Chief Financial Officer -
Steven Altschuler,
Independent Chairman of the Board of Director -
Yun Bai,
VP & Head of CMC -
Amanda Hill,
VP of People & Culture -
Melissa Abel,
VP of Commercial Strategy & Communication -
Shiva K. Natarajan,
VP of Fin. & Principal Accounting Officer -
Ram Waisbourd,
COO & Chief Bus. Officer -
Ryan Stephen Martins,
Chief Financial Officer -
Charles Mc Wherter,
-
Tomer Pontifax (Israel) V, ...,
-
Capital Management, L.P.Ra ...,
-
Advisors Llc Orbi Med Capit...,
-
Capital Partners Iii, Llc L...,
-
Kathleen Laporte,
-
Edward Morrow Iii Atkinson,
-
Capital Management, L.P.Ra ...,
-
Harry H Mansbach,
Chief Medical Officer -
Lota S. Zoth,
-
Martin Babler,
-
Francis Willard Sarena,
Chief Operating Officer